Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson’s disease
Open Access
- 28 February 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (7) , 2717-2722
Abstract
An increase in the efficiency of clinical trial conduct has been successfully demonstrated in the oncology field, by the use of multi-arm, multi-stage trials allowing the evaluation of multiple therapeutic candidates simultaneously, and seamless recruitment to phase 3 for those candidates passing an interim signal of efficacy. Replicating this complex innovative trial design in diseases such as Parkinson’s disease is appealing, but in addition to the challenges associated with any trial assessing a single potentially disease modifying intervention in Parkinson’s disease, a multi-arm platform trial must also specifically consider the heterogeneous nature of the disease, alongside the desire to potentially test multiple treatments with different mechanisms of action. In a multi-arm trial, there is a need to appropriately stratify treatment arms to ensure each are comparable with a shared placebo/standard of care arm; however, in Parkinson’s disease there may be a preference to enrich an arm with a subgroup of patients that may be most likely to respond to a specific treatment approach. The solution to this conundrum lies in having clearly defined criteria for inclusion in each treatment arm as well as an analysis plan that takes account of predefined subgroups of interest, alongside evaluating the impact of each treatment on the broader population of Parkinson’s disease patients. Beyond this, there must be robust processes of treatment selection, and consensus derived measures to confirm target engagement and interim assessments of efficacy, as well as consideration of the infrastructure needed to support recruitment, and the long-term funding and sustainability of the platform. This has to incorporate the diverse priorities of clinicians, triallists, regulatory authorities and above all the views of people with Parkinson’s disease.Keywords
Funding Information
- Edmond J. Safra Foundation
This publication has 17 references indexed in Scilit:
- A New Approach to the Development of Disease‐Modifying Therapies for PD; Fighting Another PandemicMovement Disorders, 2020
- Impact ofGBA1variants on long-term clinical progression and mortality in incident Parkinson’s diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2020
- Does the MDS-UPDRS provide the precision to assess progression in early Parkinson’s disease? Learnings from the Parkinson’s progression marker initiative cohortJournal of Neurology, 2019
- LRRK2 activation in idiopathic Parkinson’s diseaseScience Translational Medicine, 2018
- Short‐ and long‐term cost and utilization of health care resources in Parkinson's disease in the UKMovement Disorders, 2018
- Subtypes of Parkinson’s Disease: What Do They Tell Us About Disease Progression?Current Neurology and Neuroscience Reports, 2017
- The DIAN‐TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression modelAlzheimer's & Dementia, 2016
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialThe Lancet, 2016
- Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) projectThe Lancet Psychiatry, 2016
- Glucocerebrosidase mutations influence the natural history of Parkinson’s disease in a community-based incident cohortBrain, 2013